All In Biotech

NDA 018578 · Dr Reddys

Ssd Af

Silver Sulfadiazine · Topical · Sulfonamide Antibacterial

Last checked: Nov 20, 2026Latest source record: Apr 21, 2014 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1982

Feb 25, 1982

Approved uses

1

Original approval plus efficacy supplements

Registered trials

51

7 Phase 3, 3 recruiting

FAERS reports

1,422

942 serious, 177 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 31, 2026.

INDICATIONS AND USAGE Silver Sulfadiazine Cream is a topical antimicrobial drug indicated as an adjunct for the prevention and treatment of wound sepsis in patients with second and third degree burns.

Therapeutic areas: Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Feb 25, 1982 Original approval · Type 5 - New Formulation or New Manufacturer
2 products under this application
  • SSD AF · SILVER SULFADIAZINE 1% · CREAM, TOPICAL · Discontinued
  • SSD · SILVER SULFADIAZINE 1% · CREAM, TOPICAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Silver Sulfadiazine" as an intervention, any sponsor and status, largest first.

All 51 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • product use in unapproved indication133
  • off label use114
  • pain97
  • fatigue87
  • chronic kidney disease86
  • drug ineffective77
  • death73
  • diarrhoea68
  • acute kidney injury66
  • nausea66
  • anxiety63
  • pneumonia63

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20049
200514
200611
200716
20084
200917
201014
201117
201235
201324
201432
201537
201679
201777
2018107
2019119
2020126
2021176
2022127
2023114
202488
202585
202693

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Ssd (Silver Sulfadiazine)

2024 spending

$5.2M

Beneficiaries

184,885

287,522 claims

Per beneficiary

$28

$0.12 per unit

View as table
YearSpending
2020$5,905,611
2021$5,722,093
2022$5,566,987
2023$4,560,343
2024$5,205,910

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 193 on PubMed

Sponsor: Dr Reddys · Also marketed as Ssd

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.